Ultragenyx Pharmaceutical Inc. (RARE) financial statements and ratios from SEC XBRL: revenue $0.7B (TTM), net margin -85.4%, revenue growth 28.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $673.00M |
| Revenue (TTM) | $0.7B |
| Net Margin | -85.4% |
| Operating Margin (TTM) | -73.6% |
| Revenue Growth (YoY) | 28.5% |
| EPS Growth (YoY) | -23.1% |
| FCF Growth (YoY) | -11.5% |
| Price / Sales | 3.62 |
| FCF Yield | -18.9% |
| Altman Z-Score | -3.46 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
RARE overview · RARE earnings · RARE KPIs · RARE documents · RARE ownership · RARE peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.